Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

Exploring why children have milder COVID-19 infections compared to adults

A new study has revealed that an activated pre-exposure innate interferon response in airways together with significantly reduced systemic interferon-stimulated populations are associated with relatively milder severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children.

23 Dec 2021

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Researchers developed four distinct recombinant vesicular stomatitis virus (rVSV)-based bivalent vaccines against SARS-CoV-2 and influenza virus.

22 Dec 2021

Exploring the Mediterranean diet as a potential strategy against SARS-CoV-2

A study found that the Mediterranean diet, when combined with non-smoking and regular physical activity, can lower susceptibility to SARS-CoV-2.

22 Dec 2021

Impact of acute kidney injury associated gene expression in human kidney cells

A new study attempts to perform a comparative single-cell census of human kidneys employing samples from individuals suffering from acute kidney injury and controls without the condition.

20 Dec 2021

Echinacea purpurea may help prevent respiratory tract infections during COVID-19 pandemic

A new study describes the results of using an extract of the medicinal plant Echinacea purpurea to treat non-severe cases of COVID-19.

19 Dec 2021

Long-term characteristics of long-COVID following hospitalization

A new study demonstrates the urgent need for healthcare services to support this huge and quickly growing patient population, which has a significant burden of symptoms, lower exercise ability, and significant reductions in health-related quality of life after one year.

17 Dec 2021

New mRNA vaccine platform provides stronger protection against SARS-CoV-2 delta variant

A group of researchers from various institutions developed a nucleoside-modified mRNA vaccine that encodes the SARS-CoV-2 N protein (mRNA-N) and is formulated in lipid nanoparticles for this investigation (LNP).

14 Dec 2021

Bioinformatics pipeline can be used to quickly identify SARS-CoV-2 therapeutics

In a new study, researchers developed a bioinformatics pipeline that uses RNA sequencing data to identify altered genes and signaling pathways affected by viral infection.

13 Dec 2021

Convalescent plasma not recommended for patients with covid-19, WHO experts say

Convalescent plasma (a transfusion of blood plasma from someone who has recovered from covid-19) is not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.

7 Dec 2021

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

In a recent study conducted at Yale University, USA, scientists have investigated the immunogenicity of mRNA-based coronavirus disease 2019 (COVID-19) vaccine candidates encoding the spike proteins of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The findings reveal that the vaccines induce robust immune responses against SARS-CoV-2 variants. The study is currently available on the bioRxiv* preprint server.

6 Dec 2021

Novel monoclonal antibody could help revolutionize treatment of children with high-risk neuroblastoma

Survival rates increased about 20% for children with high-risk neuroblastoma enrolled in a St. Jude Children’s Research Hospital clinical trial that included a novel monoclonal antibody produced onsite. The findings appeared today in the Journal of Clinical Oncology.

6 Dec 2021

'Combination' adjuvant may boost the protective power of vaccines

Scientists at La Jolla Institute for Immunology and Massachusetts Institute of Technology, have found a possible way to improve the effectiveness of COVID-19 vaccines - and any vaccine.

4 Dec 2021

Cedars-Sinai researchers uncover the cause of UTI-induced delirium

Cedars-Sinai researchers have found that blocking the action of a protein called interleukin 6 (IL-6), part of the immune system, could resolve the delirium that often accompanies urinary tract infection (UTI) in elderly patients.

2 Dec 2021

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

A new study evaluates the efficacy of SNX-5422 as a post-exposure prophylactic treatment.

23 Nov 2021

Preexisting rhinovirus infection and IFN induction in epithelium of asthma patients decreases SARS-CoV-2 infection

In a recent study, researchers explored the effects of RV, HDM, and SARS-CoV-2 on differentiated primary human bronchial epithelial cells (HBECs) in vitro and in experimental in vivo RV infection in healthy subjects and asthmatic patients.

22 Nov 2021

Giving social support to others may play an important role in health

When it comes to your health, being willing to give social support to your spouse, friends and family may be just as important as receiving assistance, a new study suggests.

22 Nov 2021

Paper-based innovations for COVID-19 diagnosis

A review discusses paper-based devices and platforms targeting SARS-CoV-2 for low-cost PoC diagnosis and serological antibody testing.

22 Nov 2021

A trio of proteins found to drive inflammation in psoriasis

About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as patches of red, inflamed skin and painful, scaly rashes. Although there are effective treatments for psoriasis, not everyone responds to these therapies - and for many, the relief is temporary.

21 Nov 2021

Comparing effectiveness of virus and patients-centered strategies to reduce COVID-19 mortality

Researchers from Sorbonne Université have been reviewing papers exploring different anti-COVID-19 drugs.

19 Nov 2021

Researchers receive $22 million grant for clinical trial that aims to reduce lung transplant rejection

Physicians at Washington University School of Medicine in St. Louis and Massachusetts General Hospital/Harvard Medical School in Boston have received a seven-year, $22 million grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to help lead a multicenter clinical trial evaluating whether a novel immunosuppressant can reduce the risk of organ rejection after a lung transplant.

18 Nov 2021

Interleukin 6 News and Research

Further Reading

Exploring why children have milder COVID-19 infections compared to adults

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Exploring the Mediterranean diet as a potential strategy against SARS-CoV-2

Impact of acute kidney injury associated gene expression in human kidney cells

Echinacea purpurea may help prevent respiratory tract infections during COVID-19 pandemic

Long-term characteristics of long-COVID following hospitalization

New mRNA vaccine platform provides stronger protection against SARS-CoV-2 delta variant

Bioinformatics pipeline can be used to quickly identify SARS-CoV-2 therapeutics

Convalescent plasma not recommended for patients with covid-19, WHO experts say

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

Novel monoclonal antibody could help revolutionize treatment of children with high-risk neuroblastoma

'Combination' adjuvant may boost the protective power of vaccines

Cedars-Sinai researchers uncover the cause of UTI-induced delirium

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

Preexisting rhinovirus infection and IFN induction in epithelium of asthma patients decreases SARS-CoV-2 infection

Giving social support to others may play an important role in health

Paper-based innovations for COVID-19 diagnosis

A trio of proteins found to drive inflammation in psoriasis

Comparing effectiveness of virus and patients-centered strategies to reduce COVID-19 mortality

Researchers receive $22 million grant for clinical trial that aims to reduce lung transplant rejection

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News